Progen Pharmaceuticals, formerly known as CellGate, is a subsidiary of Progen Pharmaceuticals Limited. They specialize in developing anti-proliferative therapeutics that target proliferating cells and induce cell death to halt the progress of diseases. They have a portfolio of oncology candidates, including one in Phase 1 clinical trials, and are advancing a range of novel anti-proliferation therapeutics for patients.